Lutetium lu 177 vipivotide tetraxetan
EndolucinBeta, Lumark, Pluvicto (lutetium lu 177 vipivotide tetraxetan) is a small molecule pharmaceutical. Lutetium lu 177 vipivotide tetraxetan was first approved as Lumark on 2015-06-18. It has been approved in Europe to treat radionuclide imaging.
Download report
Favorite
Events Timeline
Commercial
Clinical
Drug
Target
Variants
Financial
Trends
Safety
Events Timeline
5D
1M
3M
6M
YTD
1Y
2Y
5Y
Max
Events
FDA approval date
EMA approval date
Patent expiration date
Study first post date
Last update post date
Start date
Primary completion date
Completion date
Results first post date
Mock data
Subscribe for the real data
Subscribe for the real data
Commercial
Trade Name
FDA
EMA
No data
Drug Products
FDA
EMA
New Drug Application (NDA)
New Drug Application (NDA)
Abbreviated New Drug Application (ANDA)
Abbreviated New Drug Application (ANDA)
No data
Labels
FDA
EMA
Brand Name | Status | Last Update |
|---|---|---|
| pluvicto | New Drug Application | 2024-09-11 |
Indications
FDA
EMA
No data
Agency Specific
FDA
EMA
Expiration | Code | ||
|---|---|---|---|
LUTETIUM LU-177 VIPIVOTIDE TETRAXETAN, PLUVICTO, NOVARTIS | |||
| 2027-03-23 | NCE | ||
HCPCS
Code | Description |
|---|---|
| A9607 | Lutetium lu 177 vipivotide tetraxetan, therapeutic, 1 millicurie |
Clinical
Clinical Trials
71 clinical trials
View more details
Mock data
Subscribe for the real data
Subscribe for the real data
Indications Phases 4
Indication | MeSH | Ontology | ICD-10 | Ph 1 | Ph 2 | Ph 3 | Ph 4 | Other | Total |
|---|---|---|---|---|---|---|---|---|---|
| Prostatic neoplasms | D011471 | — | C61 | 26 | 37 | 7 | 2 | 8 | 68 |
| Castration-resistant prostatic neoplasms | D064129 | — | — | 14 | 19 | 1 | 1 | 4 | 33 |
Indications Phases 2
Indication | MeSH | Ontology | ICD-10 | Ph 1 | Ph 2 | Ph 3 | Ph 4 | Other | Total |
|---|---|---|---|---|---|---|---|---|---|
| Neoplasms | D009369 | — | C80 | 2 | 3 | — | — | 1 | 5 |
| Adenocarcinoma | D000230 | — | — | 2 | 2 | — | — | — | 3 |
| Adenoid cystic carcinoma | D003528 | — | — | 1 | 1 | — | — | — | 2 |
| Hypersensitivity | D006967 | HP_0012393 | T78.40 | — | 1 | — | — | — | 1 |
| Urogenital neoplasms | D014565 | EFO_0003863 | D07 | — | 1 | — | — | — | 1 |
| Neoplasms by site | D009371 | — | — | — | 1 | — | — | — | 1 |
| Prostatic diseases | D011469 | — | N42.9 | — | 1 | — | — | — | 1 |
| Male genital neoplasms | D005834 | — | — | — | 1 | — | — | — | 1 |
Indications Phases 1
No data
Indications Without Phase
Indication | MeSH | Ontology | ICD-10 | Ph 1 | Ph 2 | Ph 3 | Ph 4 | Other | Total |
|---|---|---|---|---|---|---|---|---|---|
| Renal cell carcinoma | D002292 | EFO_0000376 | — | — | — | — | — | 1 | 1 |
Epidemiology
Epidemiological information for investigational and approved indications
View more details
Drug
General
| Drug common name | Lutetium lu 177 vipivotide tetraxetan |
| INN | — |
| Description | EndolucinBeta, Lumark, Pluvicto (lutetium lu 177 vipivotide tetraxetan) is a small molecule pharmaceutical. Lutetium lu 177 vipivotide tetraxetan was first approved as Lumark on 2015-06-18. It has been approved in Europe to treat radionuclide imaging. |
| Classification | Small molecule |
| Drug class | peptides: (prostate-specific membrane antigen) PSMA binding peptide; chelating agents |
| Image (chem structure or protein) |  |
| Structure (InChI/SMILES or Protein Sequence) | — |
Identifiers
| PDB | — |
| CAS-ID | — |
| RxCUI | — |
| ChEMBL ID | CHEMBL4594406 |
| ChEBI ID | — |
| PubChem CID | — |
| DrugBank | — |
| UNII ID | — |
Target
No data
Variants
No data
Financial
Revenue by drug
$
€
£
â‚£
Pluvicto – Novartis
Mock data
Subscribe for the real data
Subscribe for the real data
Mock data
Subscribe for the real data
Subscribe for the real data
Tabular view
Estimated US medical usage
No data
Trends
PubMed Central
Top Terms for Disease or Syndrome:
Mock data
Subscribe for the real data
Subscribe for the real data
Additional graphs summarizing 288 documents
View more details
Safety
Black-box Warning
No Black-box warning
Adverse Events
Top Adverse Reactions
Mock data
Subscribe for the real data
Subscribe for the real data
5,282 adverse events reported
View more details
© 2020-2024 Collaborative Drug Discovery Inc. (CDD) | Terms of Use